Clinical Trial: A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07687706) titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)' on June 30.

Brief Summary: Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent ac...